Baidu
map

JPD:帕金森患者,长期的认知和运动障碍变化规律有何特点?

2022-03-20 freeman爱科学 MedSci原创

在三年的时间里,不同的PD运动表型有不同的神经心理学进展模式。

人们越来越努力地确定帕金森病(PD)中认知能力下降和发生痴呆的潜在风险因素。大约30-40%的帕金森病患者存在认知障碍,患病率在病程中不断增加,10年后可达50%,在诊断后20年达到80%。

与帕金森病相关的认知状况是异质性的。由于已知的前纹状体功能障碍,执行功能以及注意力和工作记忆方面的缺陷经常出现在PD的早期阶段。PD晚期的痴呆症发病率很高,约为50%,其认知状况通常与记忆和视觉空间能力的额外缺陷有关,这被认为是晚期颞顶功能障碍的反映。

患者可分为震颤主导型(TR-D)、姿势不稳步态障碍(PIGD)或未确定(ND)运动表型。还有人将患者分为震颤主导型、运动迟缓型和混合型表型。一些可改变的因素与PD的认知损害有关,我们以前曾表明,不同的认知特征与不同的运动表型有关。我们对LANDSCAPE队列的横断面报告,这是一项调查PD患者认知功能的多中心纵向观察研究,描述了TR-D患者的认知缺陷似乎不那么严重,而PIGD患者在执行功能方面表现较差,这又与非震颤运动评分呈负相关。

同样,运动表型也可能影响认知障碍的进展,因为有证据表明,PIGD患者不仅表现出更快的认知衰退,而且有更大的痴呆风险和更高的抑郁率。这可能与运动表型的作用和认知障碍的进展特别相关,因为最初表现为TR-D患者的病人往往在病程中转换为PIGD型。

藉此, 德国RWTH Aachen University Hospital的Jennifer Michels 利用DEMPARK/LANDSCAPE研究的长期数据,评估认知障碍的进展和运动表型对PD认知衰退的预测价值。

他们纳入了711名PD患者的人口统计学、临床和神经心理学六年的纵向数据(年龄:M = 67.57;67.4%为男性)。并计算了认知领域的Z转换综合得分。对年龄、性别、教育和疾病持续时间进行了分析控制。

为了尽量减少数据缺失和辍学,他们使用线性混合模型评估了442名PD患者的三年随访数据,以了解运动表型对认知能力下降的具体作用(年龄:M=66.10;68.6%的男性)。

他们发现:在疾病的过程中,运动症状增加,而MMSE和PANDA在所有亚组中保持稳定。

经过三年的随访,PIGD患者的整体认知能力明显下降,运动表型在注意力(β=-0.08,SE=0.003,p<0.006)和记忆功能方面存在差异,显示PIGD患者与ND组相比,每个月恶化-0.006(SE = 0.003,p = 0.046)。

此外,PIGD患者在日常生活中更经常遇到困难。

该研究的重要意义在于发现了:在三年的时间里,不同的PD运动表型有不同的神经心理学进展模式,早期的执行缺陷在后期的过程中产生了更多的失忆特征。特别是PIGD患者与TR-D和ND患者相比,随着时间的推移而恶化,突出表明这种运动表型的痴呆风险更大。

原文出处:
Michels J, Storch A, Linse K, et al. Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson’s Disease.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-04-17 qinhuang

    写的很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-24 qinhuang

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-21 明二公子

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-21 仁术2021

    不错,学习了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1212044, encodeId=9fdd1212044fd, content=写的很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Sun Apr 17 23:59:24 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205691, encodeId=9e18120569126, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d0d480788, createdName=qinhuang, createdTime=Thu Mar 24 22:08:48 CST 2022, time=2022-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368819, encodeId=0bcd1368819ee, content=<a href='/topic/show?id=b40b9423884' target=_blank style='color:#2F92EE;'>#运动障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94238, encryptionId=b40b9423884, topicName=运动障碍)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Mon Mar 21 13:34:57 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204547, encodeId=83e5120454e16, content=学习了 , beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210715/616fc3ab029343e2bfeb665e382ab64f/81511186951542fcb876d02ae61bc3fe.jpg, createdBy=a5412034805, createdName=明二公子, createdTime=Mon Mar 21 09:49:02 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204512, encodeId=0f4a1204512a5, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Mon Mar 21 06:58:41 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204482, encodeId=50e41204482d1, content=受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/15/f4a39912ff6c27452e6ae02a2e312a5f.jpg, createdBy=6d8d1870826, createdName=果果love, createdTime=Sun Mar 20 23:02:25 CST 2022, time=2022-03-20, status=1, ipAttribution=)]
    2022-03-20 果果love

    受益匪浅

    0

相关资讯

JPD:帕金森患者,抑郁状态可预测未来神经功能紊乱

抑郁症对PD早期和中期的自主神经症状的重要影响,这与运动症状无关

JPD:帕金森患者呼出的气体分析,有助于疾病诊断和分型

呼吸分析显示了PD诊断和监测的潜力

JPD:浙江大学:神经影像助力深部脑刺激,治疗帕金森病

术前MRI指导下的STN定位结果,大约有14%的病例需要重新定位电极

JPD:智商和教育程度,和未来帕金森病风险是否相关?

年轻时的智力、教育和身体高度与男性以后患PD的风险呈正相关

JPD:多系统萎缩患者,前期都有哪些表现?

前驱性MSA进展迅速,通常没有实质性的自主神经功能障碍

JPD:帕金森病的前驱症状,有何特点?

大约11%的中年晚期人口有两个或更多的已知PD危险因素

拓展阅读

Molecular Psychiatry:实验性帕金森病中L-Dopa的奖赏特性由背侧纹状体中敏化的多巴胺D1受体介导

L-Dopa在6-OHDA损伤小鼠中获得了奖赏特性,表现为位置偏好和运动敏化,这些效应通过背侧纹状体中的D1受体介导,并伴随ΔFosB表达的增加。

Cell子刊:中国科学院叶克强等表明肠道诱导的α-突触核蛋白和Tau蛋白能够同时引发帕金森病和阿尔茨海默病!

该研究表明肠道诱导的α-突触核蛋白和Tau蛋白繁殖引发帕金森病和阿尔茨海默病的共同病理和行为障碍。

【今日分享】德国神经病学学会关于帕金森病患者认知障碍和情感障碍的诊断和治疗指南:诊断程序和非药物干预的新亮点

认知障碍和痴呆以及情感障碍是帕金森病 (PwPD) 患者中常见的致残综合征。作者总结了德国神经学会 (DGN) 2023 年更新的德国“帕金森病”指南的建议,重点关注这些疾病的

论著|视觉诱发电位评估帕金森病视幻觉视觉传导通路临床价值

本研究通过对伴有视幻觉的帕金森病患者进行视觉诱发电位的检测,以探讨视觉传导通路在帕金森病患者出现视幻觉中的作用。

MIND饮食:能预防老年痴呆和帕金森病?

健脑饮食,又称 MIND 饮食,是一种针对大脑健康的饮食法,这种饮食相对较新颖,不属于生酮饮食,但是低碳水饮食的一种。它结合了地中海饮食和 DASH 饮食。

Neurology:帕金森病患者结构脑网络弹性和拓扑结构的病理改变

本研究结果强调,区域网络干扰的解释比以前认为的要复杂得多。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

Baidu
map
Baidu
map
Baidu
map